Nektar Therapeutics (NKTR) Reaches $72.53 52-Week High; Conns (CONN) Sentiment Is 1.29

January 16, 2018 - By Vivian Currie

Conn's, Inc. operates as a specialty retailer of durable consumer goods and related services in the United States. The company has market cap of $1.12 billion. It operates through two divisions, Retail and Credit. It has a 360.61 P/E ratio. The companyÂ’s stores provide furniture and mattress, including furniture and related accessories for the living room, dining room, and bedroom, as well as traditional and specialty mattresses; home appliances comprising refrigerators, freezers, washers, dryers, dishwashers, and ranges; and home office products consisting of computers, printers, and accessories.

The stock of Nektar Therapeutics (NASDAQ:NKTR) hit a new 52-week high and has $76.88 target or 6.00% above today’s $72.53 share price. The 8 months bullish chart indicates low risk for the $11.42 billion company. The 1-year high was reported on Jan, 16 by Barchart.com. If the $76.88 price target is reached, the company will be worth $685.26M more. The stock increased 0.74% or $0.53 during the last trading session, reaching $72.53. About 1.07M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since January 16, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.

Investors sentiment decreased to 1.4 in 2017 Q3. Its down 0.49, from 1.89 in 2017Q2. It worsened, as 15 investors sold Nektar Therapeutics shares while 52 reduced holdings. 26 funds opened positions while 68 raised stakes. 148.76 million shares or 1.09% more from 147.16 million shares in 2017Q2 were reported. Goldman Sachs Gru has 949,025 shares for 0.01% of their portfolio. Texas-based Teacher Retirement Systems Of Texas has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). Savings Bank Of America De owns 545,701 shares. Jpmorgan Chase And Com has 2.32 million shares for 0.01% of their portfolio. Blair William Il reported 0.06% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Nj State Employees Deferred Compensation Plan has 0.09% invested in Nektar Therapeutics (NASDAQ:NKTR) for 20,000 shares. Schroder Investment Management Gp holds 7,341 shares or 0% of its portfolio. Citigroup holds 117,936 shares. 95,730 were reported by Thrivent For Lutherans. Legal & General Group Public Ltd Co reported 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Rhumbline Advisers stated it has 317,292 shares or 0.02% of all its holdings. First Tru Advsr L P accumulated 1.66M shares. Everence Cap Mngmt Incorporated invested in 0.06% or 10,150 shares. Neuberger Berman Group Llc owns 224,900 shares. 5,603 are owned by Zurcher Kantonalbank (Zurich Cantonalbank).

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on March, 7. They expect $-0.35 earnings per share, down 25.00% or $0.07 from last year’s $-0.28 per share. After $0.37 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -194.59% negative EPS growth.

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 21 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by J.P. Morgan on Tuesday, July 18. The rating was initiated by Aegis Capital with “Buy” on Tuesday, November 8. On Monday, November 13 the stock rating was maintained by Roth Capital with “Buy”. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Jefferies on Wednesday, October 18. The company was maintained on Wednesday, August 30 by Roth Capital. Roth Capital maintained the shares of NKTR in report on Tuesday, May 30 with “Buy” rating. On Thursday, January 7 the stock rating was maintained by Piper Jaffray with “Overweight”. Canaccord Genuity initiated the shares of NKTR in report on Thursday, November 9 with “Buy” rating. The firm has “Buy” rating by Roth Capital given on Thursday, July 20. Roth Capital maintained it with “Buy” rating and $32.5000 target in Wednesday, August 9 report.

Since August 16, 2017, it had 0 buys, and 18 sales for $19.24 million activity. CHESS ROBERT sold 6,400 shares worth $139,008. On Wednesday, December 13 the insider ROBIN HOWARD W sold $4.64 million. Another trade for 3,177 shares valued at $61,380 was sold by Labrucherie Gil M. Shares for $109,850 were sold by Lingnau Lutz. The insider Hora Maninder sold 7,583 shares worth $189,575. 2,648 shares valued at $51,159 were sold by Thomsen Jillian B. on Wednesday, August 16. 1,701 shares valued at $32,863 were sold by Doberstein Stephen K on Wednesday, August 16.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $11.42 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Since January 1, 0001, it had 3 insider purchases, and 1 sale for $53.27 million activity.

Analysts await Conn's, Inc. (NASDAQ:CONN) to report earnings on April, 3. They expect $0.49 EPS, up 880.00% or $0.44 from last year’s $0.05 per share. CONN’s profit will be $15.37M for 18.21 P/E if the $0.49 EPS becomes a reality. After $0.18 actual EPS reported by Conn's, Inc. for the previous quarter, Wall Street now forecasts 172.22% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.